Reshaping the HIV treatment and prevention landscape slide image

Reshaping the HIV treatment and prevention landscape

LA pipeline with opportunity for revenue renewal post DTG LOE Portfolio transition through decade with LA regimens ~ £2bn by 2026 gsk 2021-26 growth drivers Dovato Cabenuva 2026 Portfolio Mix Cab PrEP Oral portfolio LA portfolio launching by 2022 DTG dolutegravir; LoE loss of exclusivity Post 2026 LA pipeline growth drivers Self Admin for Treatment Ultra LA for Treatment Ultra LA for PrEP 75
View entire presentation